Cadila (lipaglyn) and biocon are doing it. I am invested in both because their business is not entirely dependent on new molecules and they trade at fair valuations w.r.t. their current business!

Quoting for the Business Today article:
"Our profit margins are miniscule because the main aim is not to make profit," says Ramdev.

Surely, they can be disruptive if they provide same quality at much less cost. But how sustainable can that be, working without profits? Will suppliers, employees, distributors, retailers also work without profit?

Software product cos. have habit of acquiring research at inflated prices and Take Soln. is no different. Capital allocation has been poor in the past. They took debt to acquire assets which did not yield good enough results and hence debt never really came down. Someone compared FY11 and FY15 profits and it appears that they have stagnated. In reality, EBITDA has grown in line with sales but accelerating depreciation (and amortisation?) has kept PAT in check. I haven't done study on why its recent acquisition should work.

Disc: No holdings

possible.. by the way... since the stock can go up tomorrow, i think there's still something missing in my understanding... and this makes me sad because there's definitely something that is not outlined in that notice which is playing a part in deciding the price.. will try to clarify this with bse tomorrow

Hi,

I know during ANDA filing the formulation maker has to identify the API source.
For the drugs that are coming off patent, Is there anyway to find out how many formulation makers are using Neuland as API source ?? I see that only as any hope to see topline growth.

Also,
One question is that why do formulation makers buy API from other when they can produce it themselves ?